Bicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results, Meets Estimates

Posted by Stanley Muller on Aug 13th, 2026

Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.82) EPS for the quarter, meeting the consensus estimate of ($0.82), Zacks reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

Management highlighted three-year follow-up data for FICERA in HPV-negative head and neck cancer, saying approximately one in three patients remained alive at three years—nearly double retrospective standard-of-care estimates—while maintaining a consistent safety profile.
The pivotal FORTIFI-HN01 study remains on track for substantial enrollment by year-end, with more than 200 sites active and a planned interim analysis in mid-2027 that could support a potential accelerated approval.
Bicara initiated the FORTIFI-FLEX study to evaluate loading and every-three-week maintenance dosing, aiming to have data available by a potential U.S. approval and support inclusion of a more convenient regimen in the product label.
The company reported approximately $497 million in cash and marketable securities at quarter-end, providing projected runway into the first half of 2029, while warning that operating expenses will rise as pivotal-trial, manufacturing, medical-affairs, and commercial-launch investments increase.
Leadership transitions will take effect as Ryan Cohlhepp becomes CEO and Claire Mazumdar moves to vice chair and strategic advisor; Bicara also announced new finance, operations, business, and legal leadership intended to support potential commercialization.

Bicara Therapeutics Stock Up 3.7%

NASDAQ BCAX opened at $24.63 on Thursday. The firm has a market cap of $1.62 billion, a P/E ratio of -7.95 and a beta of -0.75. Bicara Therapeutics has a 52-week low of $10.30 and a 52-week high of $30.99. The business’s 50-day moving average price is $26.00 and its 200 day moving average price is $21.74.

Insider Transactions at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 18,750 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total transaction of $524,625.00. Following the completion of the sale, the chief operating officer directly owned 181,641 shares of the company’s stock, valued at $5,082,315.18. This trade represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the completion of the transaction, the chief executive officer owned 362,152 shares in the company, valued at approximately $10,133,012.96. This trade represents a 2.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 129,700 shares of company stock worth $3,520,725 over the last 90 days. 13.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCAX. Legal & General Group Plc boosted its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the period. Larson Financial Group LLC boosted its position in shares of Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. American Century Companies Inc. acquired a new position in shares of Bicara Therapeutics during the 2nd quarter worth $103,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Bicara Therapeutics by 87.5% in the 4th quarter. New York State Common Retirement Fund now owns 7,500 shares of the company’s stock valued at $126,000 after purchasing an additional 3,500 shares in the last quarter.

Bicara Therapeutics News Summary

Here are the key news stories impacting Bicara Therapeutics this week:

Positive Sentiment: Bicara reported second-quarter loss of $0.82 per share, matching consensus expectations. More importantly, management said enrollment in its pivotal cancer study remains on track for 2026, providing a potentially important clinical catalyst. Bicara Therapeutics stock gains as pivotal trial enrollment advances
Positive Sentiment: Analyst sentiment improved following the quarterly update. BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, while other analysts also lifted forecasts. The broader consensus remains a Moderate Buy with an average target of approximately $32.73. Analysts raise Bicara Therapeutics forecasts
Positive Sentiment: Wedbush reiterated that Bicara’s cancer study is on track for 2026 enrollment, supporting the view that the company could deliver meaningful development milestones in the near term. Bicara Therapeutics cancer study remains on track
Neutral Sentiment: Analyst views remain mixed. Wells Fargo raised its target from $16 to $23 but kept an Equal Weight rating, while other firms maintain more bullish targets. Bicara also announced strategic leadership transitions as it enters its next execution phase. Wells Fargo price-target update
Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep sold a combined 41,250 shares for about $1.15 million. The transactions were made under pre-arranged Rule 10b5-1 plans, and the executives retained substantial stakes, which reduces—but does not eliminate—the negative signal from the insider selling. Bicara insider transaction filings

Analyst Upgrades and Downgrades

Several equities analysts have commented on BCAX shares. Wall Street Zen raised shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. The Goldman Sachs Group increased their price objective on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday. Guggenheim initiated coverage on shares of Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price objective for the company. Wells Fargo & Company boosted their target price on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Finally, BTIG Research increased their target price on Bicara Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.73.

Check Out Our Latest Stock Report on BCAX

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.